Transcode Therapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
Transcode Therapeutics Operating Expenses Growth & History (RNAZ)
Transcode Therapeutics's operating expenses was $28.0M for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $28.0M | $12.3M | +78.66% |
| 2024 | 2024-12-31 | $15.7M | −$3.8M | −19.35% |
| 2023 | 2023-12-31 | $19.4M | $784,688 | +4.21% |
| 2022 | 2022-12-31 | $18.6M | $12.5M | +202.93% |
| 2021 | 2021-12-31 | $6.2M | $5.4M | +746.56% |
| 2020 | 2020-12-31 | $726,604 | — | — |
Transcode Therapeutics quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.8M | $2.6M | +60.85% |
| Q1 2026 | 2026-03-31 | $17.8M | $14.6M | +459.89% |
| Q4 2025 | 2025-12-31 | $16.0M | $10.9M | +214.72% |
| Q3 2025 | 2025-09-30 | $4.6M | $2.4M | +110.64% |
| Q2 2025 | 2025-06-30 | $4.2M | −$892,782 | −17.46% |
| Q1 2025 | 2025-03-31 | $3.2M | −$117,803 | −3.58% |
| Q4 2024 | 2024-12-31 | $5.1M | $994,800 | +24.28% |
| Q3 2024 | 2024-09-30 | $2.2M | −$3.1M | −59.22% |
| Q2 2024 | 2024-06-30 | $5.1M | −$9,077 | −0.18% |
| Q1 2024 | 2024-03-31 | $3.3M | −$1.6M | −32.71% |
| Q4 2023 | 2023-12-31 | $4.1M | −$1.4M | −25.44% |
| Q3 2023 | 2023-09-30 | $5.3M | $356,692 | +7.20% |
| Q2 2023 | 2023-06-30 | $5.1M | $415,700 | +8.83% |
| Q1 2023 | 2023-03-31 | $4.9M | $1.4M | +40.55% |
| Q4 2022 | 2022-12-31 | $5.5M | $2.5M | +84.03% |
| Q3 2022 | 2022-09-30 | $5.0M | $2.6M | +109.90% |
| Q2 2022 | 2022-06-30 | $4.7M | $4.4M | +1224.03% |
| Q1 2022 | 2022-03-31 | $3.5M | $3.0M | +673.70% |
| Q4 2021 | 2021-12-31 | $3.0M | — | — |
| Q3 2021 | 2021-09-30 | $2.4M | $2.1M | +885.39% |
| Q2 2021 | 2021-06-30 | $355,528 | $263,923 | +288.11% |
| Q1 2021 | 2021-03-31 | $449,465 | — | — |
| Q3 2020 | 2020-09-30 | $239,491 | — | — |
| Q2 2020 | 2020-06-30 | $91,605 | — | — |
Transcode Therapeutics operating expenses trends
Over the last five fiscal years, Transcode Therapeutics's operating expenses increased from $726,604 to $28.0M, a change of $27.3M. The latest reported quarter, Q2 2026, shows $6.8M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗